Recurrent Childhood Soft Tissue Sarcoma: Clinical Trials

9 trials for Recurrent Childhood Soft Tissue Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 active not recruiting. 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 29Completed 8, Active not recruiting 1

Follow Recurrent Childhood Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Childhood Soft Tissue Sarcoma trials Research Report on Recurrent Childhood Soft Tissue Sarcoma

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)202018-06-052026-11-13
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)62017-09-142024-12-11
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma
Phase 2CompletedNational Cancer Institute (NCI)462012-06-182018-12-11
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Phase 2CompletedChildren's Oncology Group1182011-02-012020-05-13
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1162009-01-012015-03-30
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
trabectedin, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
Phase 2CompletedChildren's Oncology Group502008-01-012018-09-14
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
ixabepilone - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1202006-04-012014-11-14
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
oxaliplatin - Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Phase 2CompletedNational Cancer Institute (NCI)1802004-10-012013-06-05
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
imatinib mesylate, laboratory biomarker analysis, pharmacological study - Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1002002-05-012015-04-15

Narrower conditions

Neuroectodermal Tumors, Primitive, Peripheral (8)  ·  Neuroblastoma (7)  ·  Osteosarcoma (7)  ·  Hepatoblastoma (5)  ·  Rhabdomyosarcoma (4)  ·  Sarcoma (4)  ·  Wilms Tumor (4)  ·  Familial ependymoma (3)  ·  Adrenocortical Carcinoma (2)  ·  Central Nervous System Neoplasms (2)  ·  Ependymoma (2)  ·  Glioma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Medulloblastoma (2)

Broader conditions

Neoplasms (9)  ·  Neoplasms by Histologic Type (9)  ·  Neoplasms, Germ Cell and Embryonal (9)  ·  Neoplasms, Glandular and Epithelial (9)  ·  Neoplasms, Nerve Tissue (9)  ·  Neoplasms, Neuroepithelial (9)  ·  Neuroectodermal Tumors, Primitive (9)  ·  Neoplasms, Bone Tissue (8)  ·  Neoplasms, Connective Tissue (8)  ·  Neoplasms, Connective and Soft Tissue (8)  ·  Neuroectodermal Tumors (8)  ·  Neoplasms, Complex and Mixed (6)  ·  Female Urogenital Diseases (5)  ·  Female Urogenital Diseases and Pregnancy Complications (5)  ·  Kidney Diseases (5)

Interventions

cixutumumab (2)  ·  Biopsy (1)  ·  Imatinib Mesylate (1)  ·  MLN 8237 (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Nuclear Medicine Department, Hospital (1)  ·  Oxaliplatin (1)  ·  Phantoms, Imaging (1)  ·  Sirolimus (1)  ·  Specimen Handling (1)  ·  Trabectedin (1)  ·  X-Rays (1)  ·  erdafitinib (1)  ·  ixabepilone (1)  ·  olaparib (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  Children's Oncology Group (2)

Countries

United States (9)  ·  Canada (4)  ·  Puerto Rico (2)  ·  Australia (1)

Top investigators

Alice Lee (1)  ·  Brenda Weigel, MD (1)  ·  Brigitte Widemann (1)  ·  Julia Glade-Bender (1)  ·  Lars Wagner (1)  ·  Mason Bond (1)  ·  Orren Beaty (1)  ·  Sylvain Baruchel, MD (1)  ·  Yael Mosse (1)

Results publications

PMID 31401903, PMID 22088484, PMID 30777875, PMID 34435684, PMID 38815151

NIH funding

U10CA098543 (7), U10CA180886 (2), UM1CA081457 (1)